Carbamazepine Cas:298-46-4

We are Carbamazepine CAS:298-46-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Carbamazepine

Product Description:

Product Name: Carbamazepine CAS NO: 298-46-4

 

Synonyms:

5H-Dibenz[b,f]azepine-5-carboxamide;

Oxcarbazepine IMpurity A;

Carbamazepine solution ;

 

Chemical & Physical Properties:

Appearance: White to off-white powder

Assay :≥99.00%

Density: 1.266g/cm3

Boiling Point: 411℃ at 760mmHg

Melting Point: 189-192℃

Flash Point: 202.4℃

Refractive Index: 1.669

Water Solubility: pract. Insoluble

Stability: Stable under normal temperatures and pressures.

Storage Condition: 2-8℃

Vapor Pressure: 5.78E-07mmHg at 25℃

 

Safety Information:

RTECS: HN8225000

Hazard Class: 6.1(b)

Safety Statements: S22-S24-S37

HS Code: 2933990090

Packing Group: III

RIDADR: 3249

Risk Statements: R22; R42/43

Hazard Code: Xn

 

Carbamazepine, a sodium channel blocker, is an anticonvulsant drug.Target: Sodium channelCarbamazepine inhibits the binding of [3H]batrachotoxinin A 20-α-benzoate (BTX-B) to a receptor site of voltage-sensitive sodium channel with IC50 of 131 μM, to decrease the activation of sodium channel ion flux in rat brain synaptosomes. Carbamazepine does not alter basal 125I-labeled scorpion toxin binding to synaptosomes in the absence of batrachotoxin, but when batrachotoxin (1.25 μM) added, Carbamazepine inhibits the batrachotoxin-dependent increase in scorpion toxin binding in a concentration-dependent manner with IC50 of 260 μM mediated at the alkaloid toxin binding site, none of which affects [3H]saxitoxin binding. Carbamazepine at 25 mg/kg significantly increases extracellular levels of striatal and hippocampal dopamine (DA), 3,4-dihydroxyphenylalanine (DOPA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in a dose dependent manner, while Carbamazepine at 50 mg/kg significantly decreases total levels of striatal DA and DOPA as well as hippocampal HVA, but has no effect on total levels of striatal DOPAC and HVA nor on hippocampal DA, DOPA and DOPAC.

 

If you are interested in our products or have any questions, please feel free to contact us!

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.



Related Products:(1S,5R)-4-Ethoxy-4,5-dimethyl-3,6,8-trioxa-bicyclo[3.2.1]octane manufacturer | (4-Fluorphenyl)-thiolchlorformiat supplier | 2-naphthalen-1-yl-4-piperidin-1-yl-2-(2-piperidin-1-ylethyl)butanenitrile producer.

Related Products
Product Name
Ethyl 2-(2-aminothiazole-4-yl)-2-hydroxyiminoacetate View Details
Bis(triphenylphosphine)palladium(II) Dichloride Cas:13965-03-2 View Details
2-Bromo-5-(trifluoromethyl)benzonitrile View Details
brominated polystyrene Cas:88497-56-7 manufacturer 1-Methyl-4-piperidone manufacturer 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoroheptan-1-ol Cas:335-99-9 manufacturer 2-MERCAPTOPYRIDINE Cas:2637-34-5 manufacturer lithium tetraborate Cas:12007-60-2 manufacturer